Strategic Partnerships There is active collaboration activity with major players (IDT partnership in 2026 and Axio BioPharma as a preferred provider). Leverage and expand channel partnerships, co-development opportunities, and joint marketing to accelerate customer acquisition among pharma, biotech, and synthetic biology firms.

Product Momentum Recent product launches include longest sequence-perfect synthetic DNA and 50 kb Clonal DNA, signaling a capability to handle large, high-fidelity gene synthesis at scale. Use-case expansion to gene therapy, agriculture, and industrial biotech with high-value DNA constructs.

Executive Leadership Key hires in 2025–2026 include CFO/CBOs and COO, indicating a focus on finance, governance, and scale. Align business development with enterprise sales cycles, provide ROI-focused value propositions, and prepare for larger deal structures and contract negotiations.

Industry Validation Public statements and conference presence (SynBioBeta 2026) plus a client win from Axio BioPharma demonstrate credibility and market interest. Target research institutions, biotech startups, and contract manufacturers seeking scalable DNA synthesis, emphasizing reliability and throughput improvements.

Global Growth Funding level around $130M and revenue in the mid-range suggest growth runway and opportunity for enterprise customers. Highlight scalable production capabilities, support services, and long-term supply agreements to convert prospects into strategic customers.